Clinical study of effect of low dose atropine drops on progression of myopia in children
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242297Keywords:
Myopia, Atropine, Axial length, Macular thickness, Spherical equivalentAbstract
Background: As an eye condition, myopia is prevalent and often confusing. In modern times, a higher risk of many eye illnesses is linked to myopia, even at modest levels. Improving eye health and quality of life may be possible by halting the development of myopia.
Methods: It was a prospective, experimental study, designed to look at the effect of 0.01% atropine eye drop on myopia progression, conducted in outpatient tertiary medical centre, total 66 patients were enrolled. Inclusion criteria include having age of ≥6 years and ≤15 years with myopia or myopic astigmatism and whose parents have given consent to participate in the study. Exclusion criteria include children with congenital/developmental delay or systemic diseases, ocular pathology like amblyopia, strabismus, cataract, allergy to atropine were not included.
Results: The result showed that the comparison of spherical equivalent between the baseline measurements and the follow-up measurements after the use of low dose atropine drops indicates that a significant correlation is found between the baseline and follow-up of 12 months (p=0.043) and 18 months (p=0.038). The 6-month follow-up comparison does not show statistically significant association.
Conclusions: We concluded that the low dose atropine should be considered as one the myopia progression control remedy. Recommendation of carry out further research in the similar population of a longer duration of three years and above to better understand the effect of low dose atropine in myopia progression should be considered.
References
Cooper J, Tkatchenko AV. A Review of Current Concepts of the Etiology and Treatment of Myopia. Eye Contact Lens. 2018;44(4):231-47.
Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31:622-60.
Holden BA. The Charles F. Prentice award Lecture 2014: A 50-year research journey: Giants and Great Collaborators. Optom Vis Sci. 2015;92:741-9.
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.
Morgan IG, Wu PC, Ostrin LA, Tideman JW, Yam JC, Lan W, et al. IMI risk factors for myopia. Investigat Ophthalmol Visual Sci. 2021;62(5):3-.
Ip JM, Saw SM, Rose KA, Morgan IG, Kifley A, Wang JJ, et al. Role of near work in myopia: findings in a sample of Australian school children. Investigat Ophthalmol Visual Sci. 2008;49(7):2903-10.
Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese school children: 1983 to 2000. Ann Acad Med. 2004;33(1):27-33.
Agarwal D, Saxena R, Gupta V, Mani K, Dhiman R, Bhardawaj A, et al. Prevalence of myopia in Indian school children: Meta-analysis of last four decades. PLoS one. 2020;15(10):e0240750.
Priscilla JJ, Verkicharla PK. Time trends on the prevalence of myopia in India-A prediction model for 2050. Ophthal Physiolog Opt. 2021;41(3):466-74.
Fricke TR, Holden BA, Wilson DA, Schlenther G, Naidoo KS, Resnikoff S, et al. Global cost of correcting vision impairment from uncorrected refractive error. Bull Worl Heal Organ. 2012;90:728-38.
Kempen JH, Mitchell P, Lee KE, Tielsch JM, Broman AT, Taylor HR, et al. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol. 2004;122(4):495-505.
Saxena R, Dhiman R, Gupta V, Phuljhele S, Mahajan A, Rakheja V, et al. Prevention and management of childhood progressive myopia: National consensus guidelines. Indian J Ophthalmol. 20231;71(7):2873-81.
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347-54.
Clark TY, Clark RA. Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. J Ocular Pharmacol Therapeut. 2015;31(9):541-5.
